Loading
A phase 1/2 trial of balstilimab and cyclophosphamide in pancreatic cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06782932 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 38 participants, started 2025-05-27 and due to reach its primary completion in 2028-12. Interventions recorded: AGEN2373; Balstilimab; Cyclophosphamide; GVAX; AGEN2373 (RP2D); Balstilimab; mKRASvax. Conditions listed: Pancreatic Cancer. Primary outcome: Dose Limiting Toxicities in Phase I participants; Number of participants experiencing Grade 3 or Higher study drug-related toxicities; Number of participants who form Intratumoral tertiary lymphoid structures (TLS). Pancreatic eligibility wording from the registry: "* Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Resectable pancreatic ductal adenocarcinoma, Cyclophosphamide, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.